UK begins trials of Ebola vaccine developed in just eight weeks
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Oxford scientists began developing an Ebola vaccine on 17 May, and it has now entered phase one clinical trials in the UK after regulator approval
- UK Medicines and Healthcare Products Regulatory Agency authorized human testing of the Bundibugyo Ebola vaccine after preclinical data from animal studies showed promise
- Serum Institute of India manufactured and stockpiled approximately 620,000 doses of the vaccine to clinical standards, enabling rapid trial deployment
- Dr Katrina Pollock leads the trial at Oxford, emphasizing that while the vaccine uses the same platform as the AstraZeneca COVID shot, it delivers a genetic snippet specific to the Bundibugyo Ebola strain
- Alex Sampson, a vaccine researcher, stated that all standard safety and efficacy tests are being conducted, but run in parallel to accelerate development without cutting corners
- Volunteers in the UK — 50 healthy adults aged 18–55 — will be monitored for a year, with initial immune response and side effect data expected quickly
- Partners in Uganda are preparing for future trial phases in Africa, recognizing the urgency of testing in regions directly affected by the ongoing outbreak
Why it matters: The Bundibugyo Ebola outbreak has killed 625 people and remains uncontrolled in a conflict zone, making rapid vaccine deployment critical. Developing a candidate in eight weeks — versus the typical decade — changes the timeline for outbreak response, especially with 620,000 doses already stockpiled and trials expanding to Africa.
